Researcher
Gil Awada
- Keywords:Medicine
- Disciplines:Cancer therapy, Cancer diagnosis, Cancer biology
Affiliations
- Medical Oncology (Department)
Member
From1 Nov 2021 → Today - Laboratory of Molecular and Medical Oncology (Research group)
Member
From22 Mar 2021 → Today - Faculty of Medicine and Pharmacy (Faculty)
Member
From4 Oct 2015 → Today - Internal medicine (Department)
Member
From1 Sep 2021 → 31 Oct 2021 - Medical Oncology (Department)
Member
From1 Aug 2021 → 31 Aug 2021 - Clinical sciences (Department)
Member
From8 Apr 2019 → 31 Jul 2021 - Clinical sciences (Department)
Member
From1 Oct 2017 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From13 Jul 2017 → 18 Jun 2021 - Internal medicine (Department)
Member
From1 Aug 2016 → 31 Jul 2021 - Faculty of Medicine and Pharmacy (Faculty)
Member
From1 Aug 2011 → 24 Jun 2015
Publications
1 - 10 of 39
- Assessment of Retinal Pigment Epithelium Alterations and Chorioretinal Vascular Network Analyses in Patients under Treatment with BRAF/MEK Inhibitor for Different Malignancies(2023)
Authors: Giuseppe Fasolino, Gil Awada, Laura Moschetta, Jorgos Koulalis, Bart Neyns, Bert Verhelst, Peter Van Elderen, Pieter Nelis, Paul Cardon de Lichtbuer, Wilfried Cools, et al.
- Intratumoral administration of CD1c (BDCA-1)+ and CD141 (BDCA-3)+ myeloid dendritic cells in combination with talimogene laherparepvec in immune checkpoint blockade refractory advanced melanoma patients(2022)
Authors: Julia Katharina Schwarze, Jens Tijtgat, Gil Awada, Louise Cras, Angela Vasaturo, Christopher Bagnall, Ramses Forsyth, Inès Dufait, Sandra Tuyaerts, Ivan Van Riet, et al.
Pages: 1-13 - Anti-PD-1(2022)
Authors: Y Jansen, Astrid A M van der Veldt, Gil Awada, Bart Neyns
Pages: 905-915 - A lead-in safety study followed by a phase 2 clinical trial of dabrafenib, trametinib and hydroxychloroquine in advanced BRAFV600 mutant melanoma patients previously treated with BRAF-/MEK-inhibitors and immune checkpoint inhibitors(2022)
Authors: Gil Awada, Julia Katharina Schwarze, Jens Tijtgat, Giuseppe Fasolino, Vibeke Kruse, Bart Neyns
Pages: 183-191 - Melanoma with genetic alterations beyond the BRAFV600 mutation(2022)
Authors: Gil Awada, Bart Neyns
Pages: 115-122 - COVID-19 and Cushing's disease in a patient with ACTH-secreting pituitary carcinoma(2022)
Authors: Jeroen de Filette, Bastiaan Sol, Gil Awada, Corina Emilia Andreescu, David Unuane, Sandrine Aspeslagh, Jan Poelaert, Bert Bravenboer
- Low-Dose Nivolumab with or without Ipilimumab as Adjuvant Therapy Following the Resection of Melanoma Metastases: A Sequential Dual Cohort Phase II Clinical Trial(2022)
Authors: Julia Katharina Schwarze, Soizic Garaud, Yanina Jansen, Gil Awada, Valérie Vandersleyen, Jens Tijtgat, Alexandre de Wind, Paulus Kristanto, Teofila Seremet, Karen Willard-Gallo, et al.
- Choriocapillaris Assessment In Patients Under Mek-Inhibitor Therapy For Cutaneous Melanoma(2021)
Authors: Giuseppe Fasolino, Gil Awada, Jorgos Koulalis, Bart Neyns, Peter Van Elderen, Robert W A M Kuijpers, Pieter Nelis, Marcel Ten Tusscher
Pages: 765-771 - INTRA-CRANIAL ADMINISTRATION OF CTLA-4 AND PD-1 IMMUNE CHECKPOINT-INHIBITING MONOCLONAL ANTIBODIES IN RECURRENT GLIOBLASTOMA PATIENTS: A MULTI-COHORT ADAPTIVE PHASE I CLINICAL TRIAL(2021)
Authors: Johnny Duerinck, Wietse Geens, Julia Katharina Schwarze, Cleo Bertels, Jens Tijtgat, Gil Awada, Freya Vaeyens, Louise Cras, Lynn Nijland, A. M. Van Binst, et al.
Pages: 53-53 - C-reactive protein as a biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting(2021)
Authors: Justine Lauwyck, Aline Beckwée, Arno Santens, Julia Katharina Schwarze, Gil Awada, Valérie Vandersleyen, Sandrine Aspeslagh, Bart Neyns
Pages: 371-377